Artemis Hospitals Q1 FY27: Margin Expansion Sets the Tone for a Bigger Capacity Story

Artemis Hospitals opened FY27 with a clean message for investors: growth is holding up, and profitability is improving faster than revenue. On a consolidated basis for Q1 FY27, revenue from operations rose to INR 28,732 lacs, up 12.7 percent year on year. EBITDA from operations increased to INR 5,644 lacs, up 36.4 percent, and the EBITDA margin improved to 19.6 percent from 16.2 percent a year earlier. PAT came in at INR 3,144 lacs, up 48.3 percent, and diluted EPS rose to INR 1.98.

The quarter matters not only because of the headline numbers, but because it strengthens the case that Artemis is converting operating leverage into earnings momentum. Management’s long-term thesis rests on three levers that can work together: a high-acuity clinical mix, a global medical value travel platform, and a multi-year bed expansion roadmap. Q1 FY27 adds evidence that the model is working as the company prepares for its next phase of capacity build-out.

At the center of the story is Gurugram, the flagship facility and the primary earnings engine. The hospital’s operational indicators improved in a way that supports both near-term margin delivery and medium-term scale. Bed occupancy rose to 65.7 percent from 61.2 percent in Q1 FY26. Realisations improved as ARPOB increased to INR 85,690, up 7.4 percent year on year. The company also reported ALOS improving to 3.54 days from 3.67 days, a sign of better throughput and tighter clinical and operational management.

The quarter also includes an important capacity milestone: the 300+ bed Raipur super speciality hospital commenced operations in July 2026. While Raipur’s early ramp is not broken out in the financial tables, its commissioning changes the narrative from a single flagship to a network that can expand across North and Central India. Alongside this, Artemis has executed an MSA for a 650+ bed super-specialty hospital in South Delhi with an expected operational date of Q4 FY2029, and it has described overseas growth in Mauritius through its 80-bed Artemis Curepipe Hospital and an announced 110-bed facility named Artemis Cascavelle Hospital.

What improved in Q1 FY27 and why it looks durable

The flagship Gurugram hospital posted strong year-on-year gains across the typical hospital value drivers: volumes, occupancy, and pricing. Revenue from operations at Gurugram was INR 27,849 lacs, up 15.4 percent year on year. EBITDA from operations was INR 5,626 lacs, up 32.1 percent year on year. In the detailed Gurugram financial table, total revenue was INR 28,386 lacs and EBITDA was INR 6,163 lacs, with an EBITDA margin of 22.1 percent, up from 20.5 percent.

That gap between consolidated and Gurugram margins is worth noting. Gurugram’s 22.1 percent EBITDA margin indicates that the core asset is generating strong cash earnings, while the consolidated view reflects the broader platform and the early phase of expansion. For investors, this can be a useful way to frame the next few years: the flagship funds the build-out, while new assets begin their ramp.

Operational metrics support the margin story. Operational beds at Gurugram were 544, with occupied beds at 357, and occupancy of 65.7 percent. IP volume was 9,181 in Q1 FY27. The company commentary describes the quarter as delivering strong patient demand across specialties and improving efficiency. ALOS moving down to 3.54 days suggests more efficient patient flow, which can help revenue growth without requiring proportional cost growth.

There is also a payor mix that supports premium economics. In Q1 FY27 at Gurugram, international patients accounted for 27 percent of revenue, insured patients 33 percent, domestic cash patients 23 percent, and government schemes 17 percent. International patient contribution was lower than Q4 FY26’s 31 percent and FY26’s 32 percent, but still meaningful and consistent with the company’s broader claim that about 27 to 30 percent of revenue is derived from international patients. A platform that can keep international volumes resilient while expanding domestic insured and cash segments typically has better pricing power and more stable collections.

One headwind that appears in multiple slides is other income. Other income declined in Q1 FY27, and the company attributes it to utilisation of IFC funds towards expansion projects. This matters because it indicates that earnings growth is being driven primarily by operations rather than treasury-like income, and it hints at an active capex cycle.

Financial snapshot: consolidated, standalone, and the Gurugram engine

The consolidated income statement for Q1 FY27 shows revenue growth translating into a faster rise in EBITDA, and an even faster rise in PAT. Consolidated total income was INR 29,270 lacs, up 11.8 percent year on year. EBITDA was INR 6,182 lacs, up 27.9 percent, and EBITDA margin rose to 21.5 percent from 19.0 percent. PAT was INR 3,144 lacs, up 48.3 percent, with PAT margin expanding to 10.9 percent from 8.3 percent.

Standalone numbers tell a similar story. In Q1 FY27, standalone revenue from operations was INR 28,201 lacs, up 12.9 percent year on year. EBITDA was INR 6,088 lacs, up 27.3 percent, with EBITDA margin improving to 21.6 percent from 19.1 percent. PAT increased to INR 3,105 lacs, up 45.0 percent, with PAT margin of 11.0 percent.

The common thread across these views is operating leverage. Operative expenses and employee benefit expenses rose, but at a lower pace than EBITDA. Finance costs also declined year on year in both standalone and consolidated, supporting PBT expansion. Depreciation increased, which aligns with an asset base preparing for expansion.

Strategy in motion: expansion, high-acuity mix, and global patient flows

Artemis has laid out a long-term framework that is unusually specific for a hospital platform. The company describes an integrated healthcare platform with about 800 operational beds across the flagship Gurugram hospital and allied platforms. It is also explicit about where growth is expected to come from: quaternary care, cardiac care centres, and international healthcare delivery.

The capacity plan is the most visible strategic driver. A 300+ bed Raipur super speciality hospital is now operational since July 2026, creating an additional growth engine in Central India. A 650+ bed South Delhi hospital is planned with a 30-year operating agreement structure and an expected operational date of Q4 FY2029. The company has also referenced a proposed fund raise of about INR 700 crore, approved by shareholders, to fund growth initiatives and capital requirements. Alongside greenfield and asset-light additions, Gurugram still has expansion optionality. The hospital opened a third tower that took capacity to 700 beds, and a Platinum Green Building Certification entitles a 15 percent increase in FAR, enabling about 100 additional beds. The company has also described a purchase of additional FAR to 2.15, adding about 200 more beds and taking capacity to about 950 to 1,000 beds.

From an investor perspective, a large capacity plan only matters if it sits on top of a differentiated clinical platform that can sustain premium pricing. Artemis argues it has that differentiation. It runs 14 Centres of Excellence across 40+ specialties and highlights that about 60 percent of revenue comes from high-acuity specialties. The presentation reinforces these capabilities through examples like oncology, transplants, robotic surgery, and advanced critical care, and through high-complexity patient stories.

Technology is presented as another edge. Artemis lists advanced systems such as North India’s first CyberKnife M6 system, the da Vinci robotic surgical system, a joint replacement robotic system, imaging and diagnostic platforms including PET CT, MRI, cath lab technologies, and other high-end imaging systems. These investments help explain the company’s ability to maintain high ARPOB and attract international patients seeking complex treatments.

The international platform is a major part of the Artemis identity. The company states that about 27 to 30 percent of revenue is derived from international patients and that it has a diversified patient base across more than 150 countries, with partnerships spanning Africa, CIS, the Middle East and SAARC nations. Q1 FY27 payor mix at Gurugram shows international patients at 27 percent, which sits within that stated range.

Management commentary in the presentation also focuses on patient-centric culture and ethics. The chairman’s message frames Artemis as a sanctuary of health with attention to comfort, systems, and infrastructure, backed by skilled professionals. The managing director’s message emphasises compassion, trust, empathy, integrity, and patient safety, and positions growth as a means to improve access without compromising ethical standards.

What to watch next: execution risk, ramp-up, and mix

Q1 FY27 sets a constructive baseline, but it also sets up the key questions for the next few years.

First is ramp discipline. Raipur commenced operations in July 2026 and will require patient acquisition, clinician build-out, and referral ecosystem development. Investors should watch for signs that the Gurugram playbook can translate to a new geography while maintaining clinical outcomes and cost control.

Second is mix stability. Gurugram’s Q1 FY27 payor split shows international patient contribution below Q4 FY26 and FY26 levels. That may reflect quarter-to-quarter variability, but international flows are an important driver of premium realisations. The ability to sustain international inflows while growing insured and cash segments will shape ARPOB and margins.

Third is the balance between capex and returns. The company has articulated a plan to expand to about 2,000 beds over the next 3 to 5 years and describes phased expansion to drive operating leverage and earnings growth. The near-term evidence of margin expansion is encouraging, but the medium-term outcome will depend on how quickly new capacity reaches mature utilisation.

Governance and ownership also provide context. As of June 30, 2026, promoters held 58.4 percent. International Finance Corporation held about 12.0 percent, and other holders include government entities and directors. For a scaling healthcare platform, long-term capital alignment and governance continuity matter, especially through multi-year expansions.

Closing view: disciplined execution, with growth visibility

The quarter’s theme is disciplined execution. Consolidated revenue growth of 12.7 percent translated into EBITDA growth of 36.4 percent and PAT growth of 48.3 percent, pointing to stronger operating leverage and better profitability quality. At Gurugram, rising occupancy, improving ARPOB, and better ALOS show that growth is not just pricing-driven and that throughput is improving.

Artemis is also moving from narrative to action on expansion. Raipur is now operational, South Delhi is planned with a long-term operating agreement and a clear timeline, and Gurugram has visible headroom through FAR-related additions. Add the company’s high-acuity clinical platform and international patient franchise, and Q1 FY27 reads like a quarter that strengthens the foundation before a larger capacity cycle.

For investors, the key takeaway is simple. Artemis is demonstrating that it can grow and expand margins at the same time, and it is pairing that with a defined roadmap to scale beds toward about 2,000. The next chapters will be about execution: ramping new hospitals, protecting the premium mix, and keeping margins resilient as the footprint widens.